Life Sciences

Lilly to pay $1.4B for alleged off-label promotion

Pharma Compliance Alert, January 21, 2009

Eli Lilly’s tab for allegedly promoting its antipsychotic Zyprexa for off-label uses topped $2.6 billion after it agreed to pay $1.42 billion to resolve civil and criminal allegations with the federal government.

The settlement includes a $515 million criminal fine, the largest ever in a healthcare case, and the largest criminal fine for an individual corporation ever imposed in a United States criminal prosecution of any kind, according to a Department of Justice (DOJ) press release.

Click here to read more.


0 comments on “Lilly to pay $1.4B for alleged off-label promotion


Most Popular